News | September 24, 2009

Prostate Cancer Foundation Convenes the World’s Leading Cancer Researchers

Jonathan W. Simons, M.D., president and CEO of the PCF.

September 25, 2009 - Nearly of 300 of the world’s leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village at Lake Tahoe in Nevada, is the 16th Scientific Retreat sponsored by the Prostate Cancer Foundation (PCF).

This year, it is projected that prostate cancer will take the lives of 27,000 U.S. men while 192,000 new cases are diagnosed. While the death rate from prostate cancer has been reduced by nearly 40 percent from what was once projected, the number of new cases diagnosed each year continues to rise. By 2015, the annual number of new cases may grow to 300,000.

“This meeting takes on additional urgency as it has been more than two years since there has been a government-sponsored meeting of this kind,” said Dr. Howard Soule, executive vice president and chief scientist for the PCF. “This annual meeting is a catalyst for scientific exchange and has helped accelerate scientific discovery for prostate cancer during the past decade. Some of the most promising developments on the field have come out of this meeting and the work of PCF-funded scientists.”

Scientists who are funded by the PCF are required to share updates on their project and share data at the PCF’s annual scientific retreat. This year’s meeting will include presentations on the progress of several new medications, therapies and biomarkers that hold promise for patients. A total of 81 scientific presentations on new research on treatment and prevention of early and advanced prostate cancers from 98 cancer research centers will be featured. The new data to be discussed originate from research programs in nine countries: Australia, Belgium, Canada, Israel, Italy, the Netherlands, Norway, the United Kingdom, and the United States. Since its founding, the PCF has raised more than $370 million to fund prostate cancer research that otherwise would have been left unfunded.

"An outcome of this international conference for accelerating better treatment for prostate cancer will be a new ‘game-changing research projects’ blueprint,” says Jonathan W. Simons, M.D., president and CEO of the PCF. “The PCF will be rapidly presenting the blueprint to our funding partners in prostate cancer research at the NIH, National Cancer Institute, Department of Defense, and leaders in the biotech and pharmaceutical industry. We want to remember this meeting as changing the course of prostate cancer research history for patients.”

The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for prostate cancer.

For more information: www.pcf.org

Related Content

more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system

Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

Feature | Radiation Oncology | July 05, 2017 | By Jeff Zagoudis
Image-guided radiation therapy offers great potential to improve the efficiency of treating cancer patients by more...

Photo courtesy of RaySearch

Feature | Treatment Planning | July 05, 2017 | By Jeff Zagoudis
While radiation oncologists have a number of proven techniques at their disposal for treating patients, the reality is...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Versa

Image courtesy of Elekta

News | Radiation Therapy | June 13, 2017
Radiation therapy (RT) using high-energy particles, like X-rays or electron beams, is a common and critical component...
News | Radiation Oncology | June 12, 2017
The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy...
stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body...
Sponsored Content | Case Study | Radiation Therapy | June 08, 2017
Stereotactic body radiation therapy (SBRT) employs significantly higher per fraction radiation doses than conventional...
pediatric imaging
News | Radiation Oncology | June 08, 2017
In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that e
Feature | Radiation Therapy | June 07, 2017 | By Melinda Taschetta-Millane
According to the National Institutes of Health (NIH), precision-based medicine is an emerging approach for disease tr
Overlay Init